Polymerase Chain Reaction Market is Anticipated to Grow US$ 30.3 Bn By 2030
The worldwide Polymerase Chain Reaction market measurement is anticipated to achieve USD 30.3 billion by 2030 and is anticipated to increase at a CAGR of 1.0% from 2021 to 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38466
Growth Factors
This is driven by an increase in demand for rapid diagnostic tests and technological advancements.Key players operating in the market are focusing on introducing novel and technologically advanced devices for PCR tests. For instance, in July 2017, Bio-Rad Laboratories launched droplet digital PCR Genome Edit Detection Assays to quantify the efficiency of CRISPR-Cas9 or any other genome using the technology of Bio-Rad’s droplet digital polymerase chain reaction. This technology has gained prominence over the past few years. Furthermore, the COVID-19 outbreak has increased the growth rate of dPCR technology. Several types of research activities are being conducted for proving the accuracy of the dPCR test.
Report Highlights
The others segment dominated the market and accounted for the largest revenue share of more than 95.0% in 2020. The segment includes Real-time PCR (qPCR) and digital PCR, which dominated the overall market in 2020 due to increased adoption and wide applications in research.
The consumables and reagents segment dominated the market and accounted for the largest revenue share of more than 69.0% in 2020. This growth is attributable to a substantial demand for testing supplies for the SARS-CoV-2 pandemic and the increased availability of technologically advanced diagnostic equipment in countries with unmet clinical needs.
The technology is improving and is shifting toward easy-to-use products. For instance, MatMaCorp’s handheld PCR device MYRTA was launched in May 2021 facilitating real-time detection. A new entrant diagnostic system in the segment is the QuantStudio 5 Dx RT-PCR system, which was introduced by Thermo Fisher Scientific in March 2021 for laboratory use as well as assay development.
The medical segment dominated the market and accounted for the largest revenue share of 95.9% in 2020. The segment is anticipated to maintain its dominance over the forecast period due to its advantages in research and other applications, such as detecting and quantifying low-frequency mutations and low levels of pathogens with higher sensitivity. Moreover, increasing adoption in diagnostic centers and hospitals is propelling the growth of the segment.
Increasing adoption of PCR for food safety and detecting infection along with food-borne pathogens and toxicogenic fungi is expected to drive the market. Species identification has become increasingly vital in some applications such as meat species identification.
North America dominated the Polymerase Chain Reaction market and accounted for the largest revenue share of 37.8% in 2020. Favorable government initiatives, coupled with flexible regulatory guidelines are anticipated to propel market growth in North America. For instance, in February 2020, the Department of Health and Human Services announced the authorization of emergency use of diagnostics for detection of COVID-19. This authorization increased the number of diagnostics product launches in the region.
Key Players
- Abbott
- Qiagen
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- bioMérieux SA
- F. Hoffmann-La Roche Ltd
- Agilent Technologies, Inc.
- Fluidigm Corporation
- Cytiva
- Stilla Technologies
- Microsynth AG
- JN Medsys
- Danaher Corporation
| Report Coverage | Details |
| Market Size | US$ 30.3 billion by 2030 |
| Growth Rate | CAGR of 1.0% From 2021 to 2030 |
| Base Year | 2020 |
| Historic Data | 2017 to 2020 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Type, Product, Application |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Abbott; Qiagen; Thermo Fisher Scientific, Inc.; Bio-Rad Laboratories, Inc.; bioMérieux SA; F. Hoffmann-La Roche Ltd.; Agilent Technologies, Inc.; Fluidigm Corporation; Cytiva; Stilla Technologies; Microsynth AG; JN Medsys; Danaher Corporation |
Market Segmentation
- Type
- Conventional PCR
- Others
- Product
- Consumables & Reagents
- Instruments
- Software & Services
- Application
- Medical
- Clinical
- Pathogen Testing
- Oncology Testing
- Blood Screening
- Others
- Research
- Forensic and others
- Clinical
- Non-Medical
- Food
- Others
- Medical
- Regional
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- North America
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38466
Reasons to Purchase this Report:
– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Polymerase Chain Reaction Market, By Type
7.1. Polymerase Chain Reaction Market, by Type, 2021-2030
7.1.1. Conventional PCR
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. Others
7.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global Polymerase Chain Reaction Market, By Application
8.1. Polymerase Chain Reaction Market, by Application, 2021-2030
8.1.1. Medical
8.1.1.1. Market Revenue and Forecast (2016-2030)
8.1.2. Non-Medical
8.1.2.1. Market Revenue and Forecast (2016-2030)
Chapter 9. Global Polymerase Chain Reaction Market, By Product
9.1. Polymerase Chain Reaction Market, by Product, 2021-2030
9.1.1. Consumables & Reagents
9.1.1.1. Market Revenue and Forecast (2016-2030)
9.1.2. Instruments
9.1.2.1. Market Revenue and Forecast (2016-2030)
9.1.3. Software & Services
9.1.3.1. Market Revenue and Forecast (2016-2030)
Chapter 10. Global Polymerase Chain Reaction Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Type (2016-2030)
10.1.2. Market Revenue and Forecast, by Application (2016-2030)
10.1.3. Market Revenue and Forecast, by Product (2016-2030)
10.1.4. U.S.
10.1.4.1. Market Revenue and Forecast, by Type (2016-2030)
10.1.4.2. Market Revenue and Forecast, by Application (2016-2030)
10.1.4.3. Market Revenue and Forecast, by Product (2016-2030)
10.1.5. Rest of North America
10.1.5.1. Market Revenue and Forecast, by Type (2016-2030)
10.1.5.2. Market Revenue and Forecast, by Application (2016-2030)
10.1.5.3. Market Revenue and Forecast, by Product (2016-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Type (2016-2030)
10.2.2. Market Revenue and Forecast, by Application (2016-2030)
10.2.3. Market Revenue and Forecast, by Product (2016-2030)
10.2.4. UK
10.2.4.1. Market Revenue and Forecast, by Type (2016-2030)
10.2.4.2. Market Revenue and Forecast, by Application (2016-2030)
10.2.4.3. Market Revenue and Forecast, by Product (2016-2030)
10.2.5. Germany
10.2.5.1. Market Revenue and Forecast, by Type (2016-2030)
10.2.5.2. Market Revenue and Forecast, by Application (2016-2030)
10.2.5.3. Market Revenue and Forecast, by Product (2016-2030)
10.2.6. France
10.2.6.1. Market Revenue and Forecast, by Type (2016-2030)
10.2.6.2. Market Revenue and Forecast, by Application (2016-2030)
10.2.6.3. Market Revenue and Forecast, by Product (2016-2030)
10.2.7. Rest of Europe
10.2.7.1. Market Revenue and Forecast, by Type (2016-2030)
10.2.7.2. Market Revenue and Forecast, by Application (2016-2030)
10.2.7.3. Market Revenue and Forecast, by Product (2016-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Type (2016-2030)
10.3.2. Market Revenue and Forecast, by Application (2016-2030)
10.3.3. Market Revenue and Forecast, by Product (2016-2030)
10.3.4. India
10.3.4.1. Market Revenue and Forecast, by Type (2016-2030)
10.3.4.2. Market Revenue and Forecast, by Application (2016-2030)
10.3.4.3. Market Revenue and Forecast, by Product (2016-2030)
10.3.5. China
10.3.5.1. Market Revenue and Forecast, by Type (2016-2030)
10.3.5.2. Market Revenue and Forecast, by Application (2016-2030)
10.3.5.3. Market Revenue and Forecast, by Product (2016-2030)
10.3.6. Japan
10.3.6.1. Market Revenue and Forecast, by Type (2016-2030)
10.3.6.2. Market Revenue and Forecast, by Application (2016-2030)
10.3.6.3. Market Revenue and Forecast, by Product (2016-2030)
10.3.7. Rest of APAC
10.3.7.1. Market Revenue and Forecast, by Type (2016-2030)
10.3.7.2. Market Revenue and Forecast, by Application (2016-2030)
10.3.7.3. Market Revenue and Forecast, by Product (2016-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Type (2016-2030)
10.4.2. Market Revenue and Forecast, by Application (2016-2030)
10.4.3. Market Revenue and Forecast, by Product (2016-2030)
10.4.4. GCC
10.4.4.1. Market Revenue and Forecast, by Type (2016-2030)
10.4.4.2. Market Revenue and Forecast, by Application (2016-2030)
10.4.4.3. Market Revenue and Forecast, by Product (2016-2030)
10.4.5. North Africa
10.4.5.1. Market Revenue and Forecast, by Type (2016-2030)
10.4.5.2. Market Revenue and Forecast, by Application (2016-2030)
10.4.5.3. Market Revenue and Forecast, by Product (2016-2030)
10.4.6. South Africa
10.4.6.1. Market Revenue and Forecast, by Type (2016-2030)
10.4.6.2. Market Revenue and Forecast, by Application (2016-2030)
10.4.6.3. Market Revenue and Forecast, by Product (2016-2030)
10.4.7. Rest of MEA
10.4.7.1. Market Revenue and Forecast, by Type (2016-2030)
10.4.7.2. Market Revenue and Forecast, by Application (2016-2030)
10.4.7.3. Market Revenue and Forecast, by Product (2016-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Type (2016-2030)
10.5.2. Market Revenue and Forecast, by Application (2016-2030)
10.5.3. Market Revenue and Forecast, by Product (2016-2030)
10.5.4. Brazil
10.5.4.1. Market Revenue and Forecast, by Type (2016-2030)
10.5.4.2. Market Revenue and Forecast, by Application (2016-2030)
10.5.4.3. Market Revenue and Forecast, by Product (2016-2030)
10.5.5. Rest of LATAM
10.5.5.1. Market Revenue and Forecast, by Type (2016-2030)
10.5.5.2. Market Revenue and Forecast, by Application (2016-2030)
10.5.5.3. Market Revenue and Forecast, by Product (2016-2030)
Chapter 11. Company Profiles
11.1. Qiagen
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Thermo Fisher Scientific, Inc.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Bio-Rad Laboratories, Inc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. bioMérieux SA
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. F. Hoffmann-La Roche Ltd
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Agilent Technologies, Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Fluidigm Corporation
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Cytiva
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Stilla Technologies
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Microsynth AG
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. JN Medsys
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
11.12. Danaher Corporation
11.12.1. Company Overview
11.12.2. Product Offerings
11.12.3. Financial Performance
11.12.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38466
Contact Us:
Vision Research Reports
Call: +1 9197 992 333